Mitoxantrone hydrochl / 5 mg
Products billed under this code include Mitoxantrone Hydrochloride.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Mitoxantrone Hydrochloride.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Mitoxantrone Hydrochloride | Pfizer Inc | 61703-0343-18 | 4 | $77.672 |
| Mitoxantrone Hydrochloride | Pfizer Inc | 61703-0343-65 | 5 | $97.09 |
| Mitoxantrone Hydrochloride | Pfizer Inc | 61703-0343-66 | 6 | $116.508 |
| Mitoxantrone Hydrochloride | FreseniUS Kabi USA, LLC | 63323-0132-10 | 4 | $77.672 |
| Mitoxantrone Hydrochloride | FreseniUS Kabi USA, LLC | 63323-0132-12 | 5 | $97.09 |
| Mitoxantrone Hydrochloride | Meitheal Pharmaceuticals Inc. | 71288-0178-10 | 4 | $77.672 |
| Mitoxantrone Hydrochloride | Meitheal Pharmaceuticals Inc. | 71288-0179-13 | 5 | $97.09 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $19.418 | −$10.284 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted September 17, 2026 |
| 3Q26 | $29.702 | −$8.912 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted September 15, 2026 |
| 2Q26 | $38.614 | +$7.737 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted September 15, 2026 |
| 1Q26 | $30.877 | +$7.00 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted September 15, 2026 |
| 4Q25 | $23.877 | −$5.723 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted September 8, 2026 |
| 3Q25 | $29.60 | +$1.907 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted March 10, 2026 |
| 2Q25 | $27.693 | −$33.126 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted March 10, 2026 |
| 1Q25 | $60.819 | +$6.168 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted December 19, 2025 |
| 4Q24 | $54.651 | −$0.457 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 11, 2025 |
| 3Q24 | $55.108 | +$12.439 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 11, 2025 |
| 2Q24 | $42.669 | −$0.909 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted March 11, 2025 |
| 1Q24 | $43.578 | +$2.185 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted December 19, 2024 |
| 4Q23 | $41.393 | +$12.333 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted October 10, 2024 |
| 3Q23 | $29.06 | −$20.267 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 5, 2024 |
| 2Q23 | $49.327 | −$5.557 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted February 23, 2024 |
| 1Q23 | $54.884 | +$1.546 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted December 6, 2023 |
| 4Q22 | $53.338 | +$17.552 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 22, 2023 |
| 3Q22 | $35.786 | +$1.866 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 9, 2023 |
| 2Q22 | $33.92 | +$4.518 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted December 14, 2022 |
| 1Q22 | $29.402 | +$3.117 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 8, 2022 |
| 4Q21 | $26.285 | −$2.902 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 2, 2022 |
| 3Q21 | $29.187 | −$1.663 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted June 2, 2022 |
| 2Q21 | $30.85 | +$6.71 | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted March 1, 2022 |
| 1Q21 | $24.14 | – | 5 MG | Mitoxantrone hydrochl / 5 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.